Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03288480 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Promontory Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT03288480 is a Phase 1 study that has completed, run by Promontory Therapeutics. The registered enrollment target is 24 participants.
The verdict
NCT03288480, a Phase 1 study, has completed, sponsored by Promontory Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Study PT-112-102, a multicenter, open-label dose-finding and pharmacokinetic study of PT-112 in patients with relapsed or refractory multiple myeloma. This is designed as a two-part study. In the first part of the study, cohorts of three patients (expanded to six patients in the event of a dose-limiting toxicity) will receive escalating doses of PT-112 until the MTD is reached, based on tolerability observed during the first 28 days of treatment. In the second part of the study, an expansion cohort of 14 patients will be treated at the recommended dose to confirm the tolerability of treatment and evaluate evidence of treatment efficacy.
Interventions
- DRUG PT-112
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-12-15 |
| Est. Completion | 2021-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03288480
The ClinicalTrials.gov registry entry for NCT03288480 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Promontory Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PT-112 is the first listed.
NCT03288480 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03288480 about?
NCT03288480 is a clinical study titled "A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma". Study PT-112-102, a multicenter, open-label dose-finding and pharmacokinetic study of PT-112 in patients with relapsed or refractory multiple myeloma. This is designed as a two-part study. In the first part of the study, cohorts of three patients (expanded to six patients in the event of a dose-lim...
What is the current status of trial NCT03288480?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2017-12-15. Estimated completion is 2021-03-01.
What interventions are being tested in trial NCT03288480?
The interventions under investigation include: PT-112 (DRUG).
Who is sponsoring clinical trial NCT03288480?
This trial is sponsored by Promontory Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.